From the ‡Department of Pharmacology, University of Texas Medical Branch, Galveston (UTMB), Texas, 77555;
¶Sealy Center for Molecular Medicine, UTMB, Galveston, Texas, 77555.
Mol Cell Proteomics. 2017 Nov;16(11):1906-1921. doi: 10.1074/mcp.RA117.000154. Epub 2017 Sep 5.
Rapidly proliferating tumors are exposed to a hypoxic microenvironment because of their density, high metabolic consumption, and interruptions in blood flow because of immature angiogenesis. Cellular responses to hypoxia promote highly malignant and metastatic behavior, as well as a chemotherapy-resistant state. To better understand the complex relationships between hypoxic adaptations and cancer progression, we studied the dynamic proteome responses of glioblastoma cells exposed to hypoxia via an innovative approach: quantification of newly synthesized proteins using heavy stable-isotope arginine labeling combined with accurate assessment of cell replication by quantification of the light/heavy arginine ratio of peptides in histone H4. We found that hypoxia affects cancer cells in multiple intertwined ways: inflammation, typically with over-expressed glucose transporter (GLUT1), DUSP4/MKP2, and RelA proteins; a metabolic adaptation with overexpression of all glycolytic pathway enzymes for pyruvate/lactate synthesis; and the EMT (epithelial-mesenchymal transition) and cancer stem cell (CSC) renewal with characteristic morphological changes and mesenchymal/CSC protein expression profiles. For the first time, we identified the vitamin B transporter protein TCN2, which is essential for one-carbon metabolism, as being significantly downregulated. Further, we found, by knockdown and overexpression experiments, that TCN2 plays an important role in controlling cancer cell transformation toward the highly aggressive mesenchymal/CSC stage; low expression of TCN2 has an effect similar to hypoxia, whereas high expression of TCN2 can reverse it. We conclude that hypoxia induces sequential metabolic responses of one-carbon metabolism in tumor cells. Our mass spectrometry data are available via ProteomeXchange with identifiers PXD005487 (TMT-labeling) and PXD007280 (label-free).
快速增殖的肿瘤由于其密度、高代谢消耗以及不成熟的血管生成导致的血流中断而暴露于缺氧微环境中。细胞对缺氧的反应促进了高度恶性和转移性行为,以及化疗耐药状态。为了更好地理解缺氧适应与癌症进展之间的复杂关系,我们通过一种创新的方法研究了胶质瘤细胞暴露于缺氧时的动态蛋白质组反应:使用重稳定同位素精氨酸标记定量新合成的蛋白质,并用组蛋白 H4 中轻/重精氨酸比肽的定量准确评估细胞复制。我们发现,缺氧以多种相互交织的方式影响癌细胞:炎症,通常伴有葡萄糖转运蛋白(GLUT1)、DUSP4/MKP2 和 RelA 蛋白过表达;代谢适应,所有糖酵解途径酶过表达,用于丙酮酸/乳酸合成;以及 EMT(上皮-间充质转化)和癌症干细胞(CSC)更新,具有特征性的形态变化和间充质/CSC 蛋白表达谱。我们首次鉴定出维生素 B 转运蛋白 TCN2 作为一碳代谢所必需的,其表达显著下调。此外,通过敲低和过表达实验,我们发现 TCN2 在控制癌细胞向高度侵袭性的间充质/CSC 阶段的转化中起着重要作用;TCN2 低表达的效果类似于缺氧,而 TCN2 高表达则可以逆转这种效果。我们得出结论,缺氧诱导肿瘤细胞中一碳代谢的连续代谢反应。我们的质谱数据可通过 ProteomeXchange 获得,标识符为 PXD005487(TMT 标记)和 PXD007280(无标记)。